MedTrace Logo

Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE

NCT07199894 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-09-30

No results posted yet for this study

Summary

The goal of this clinical trial is to compare combination of Solifenacin and MIrabegron in treatment of primary mono-symptomatic nocturnal enuresis in children. It will also learn about the safety of that combination. The main questions it aims to answer are:

Does combination of Solifenacin and MIrabegron lower the number of wet nights? What medical problems do participants have when taking combination of Solifenacin and MIrabegron? Researchers will compare the combination to omegapress to see if the combination works better to treat primary mono-symptomatic nocturnal enuresis.

Participants will:

Take the combination or Omegapress every day for 3 months Visit the clinic once monthly for checkups and tests Keep a diary of their symptoms and the number of wet nights

Conditions

  • Nocturnal Enuresis in Children

Interventions

DRUG

Mirabegron (beta3-adrenoceptor agonist), Anticholinergics

Anticholinergic and B3 agonist drugs used for treatment of mono-symptomatic nocturnal enuresis

DRUG

Desmopressin (DDAVP)

ADH analogue in treatment of mono-symptomatic nocturnal enuresis

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-01
Primary Completion
2025-12-01
Completion
2026-02-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07199894 on ClinicalTrials.gov